Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 15/20 | 0.75 |
| ▸ | HTT | P42858 | 3/20 | 0.57 |
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3538069 | 0.92 | DGAT1 (0.78) | DGAT1HTTKMT2ASMN1; SMN2NPC1 | |
| SCHEMBL3540550 | 0.92 | DGAT1 (0.78) | DGAT1HTTKMT2ANPC1RAB9A | |
| SCHEMBL3540579 | 0.91 | DGAT1 (0.82) | DGAT1HTTKMT2ANPC1RAB9A | |
| SCHEMBL4496447 | 0.91 | DGAT1 (0.74) | DGAT1HTTLMNAKMT2AMEN1 | |
| SCHEMBL3545114 | 0.90 | DGAT1 (0.75) | DGAT1HTTLMNAKMT2ASMN1; SMN2 | |
| SCHEMBL3541332 | 0.87 | DGAT1 (0.81) | DGAT1HTTKMT2ANPC1RAB9A | |
| SCHEMBL3547014 | 0.87 | DGAT1 (0.75) | DGAT1HTTKMT2AMEN1MAPT | |
| SCHEMBL3545486 | 0.86 | DGAT1 (0.77) | DGAT1HTTKMT2ANPC1RAB9A | |
| SCHEMBL3542139 | 0.86 | DGAT1 (0.83) | DGAT1HTTKMT2ANPC1RAB9A | |
| SCHEMBL3549653 | 0.86 | DGAT1 (0.71) | DGAT1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100317653-A1 | OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS | ASTRAZENECA AB (SE) | 2010-12-16 | — | — | US | disclosed |
| US-7795283-B2 | Oxadiazole derivative as DGAT inhibitors | ASTRAZENECA AB (SE) | 2010-09-14 | — | — | US | disclosed |
| US-20080096874-A1 | Oxadiazole Derivative as Dgat Inhibitors | ASTRAZENECA AB (SE) | 2008-04-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100317653-A1 | OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS | DGAT1, DGAT2, GPR119 | DGAT1 1/4885HTT 1370/4885LMNA 3296/4885 |
| US-20080096874-A1 | Oxadiazole Derivative as Dgat Inhibitors | DGAT1, DGAT2, GPR119 | DGAT1 1/4885HTT 1275/4885LMNA 3477/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.